We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
BSX's Weak Solvency and Cash Conversion Raise Financing Risk
Read MoreHide Full Article
Key Takeaways
BSX ended Q3 2026 with $11.95 billion in debt and $609 million in cash, straining financial flexibility.
BSX cut its 2026 free cash flow outlook to $3.6 billion amid weaker operating income and margin pressures.
BSX faces financial strain from its $2 billion buyback, $1.5 billion MiRus investment and Penumbra deal.
Boston Scientific’s (BSX - Free Report) exited the third quarter of 2026 with $609 million in cash and approximately $11.95 billion in total debt, representing gross debt leverage of 1.9 times.
Adjusted gross margin contracted 300 basis points year over year to 68%, primarily due to unfavorable manufacturing absorption following the August cybersecurity incident. Adjusted operating margin declined 150 basis points to 26.5%, while the incident reduced quarterly adjusted earnings per share by approximately $0.07.
The company expects significant gross margin pressure in 2027, reflecting continued weakness in its Electrophysiology (EP) and WATCHMAN franchises, intensifying pricing pressure in China and ongoing operational investments. These factors could constrain operating cash flow growth and delay improvement in cash conversion.
Third-quarter free cash flow totaled $867 million. BSX lowered its full-year free cash flow outlook to approximately $3.6 billion, reflecting weaker operating income expectations.
The $2 billion accelerated share repurchase, $1.5-billion MiRus investment and pending Penumbra acquisition add to the company's financial commitments. With revenues and adjusted earnings growth expected to remain challenged in 2027, sustained margin pressure, elevated financing costs and acquisition-related obligations could limit financial flexibility.
Peer Update
Edwards Lifesciences (EW - Free Report) ended third-quarter 2026 with approximately $3.1 billion in cash and cash equivalents and about $600 million in debt. Operating cash flow reached $1.27 billion during the first nine months of 2026. The company repurchased approximately $700 million of shares through September and retained about $1.3 billion under its authorization. This liquidity supports continued investment in innovation, manufacturing and capital returns.
Medtronic (MDT - Free Report) ended first-quarter fiscal 2027 with $8.82 billion in cash and investments, compared with $2.54 billion in current debt obligations. Long-term debt also declined to $25.62 billion from $26.17 billion. During the quarter, the company paid $921 million in dividends and repurchased $267 million of shares. Medtronic maintained its quarterly dividend at $0.72 per share after raising it for fiscal 2027, marking the 49th consecutive year of dividend increases. The balance-sheet position supports continued investment in higher-growth areas and targeted acquisitions while preserving shareholder returns.
BSX Stock Price Performance
Shares of Boston Scientific have lost 56% over the past year compared with the industry’s decline of 21.5%. The S&P 500 composite has grown 10.4% over the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-sales ratio (P/S) of 3.00X, above the industry mean of 2.26X.
Image Source: Zacks Investment Research
Consensus Estimate Trend for BSX
The Zacks Consensus Estimate for BSX’s 2026 earnings has moved south 2.2% over the past 30 days.
Image: Bigstock
BSX's Weak Solvency and Cash Conversion Raise Financing Risk
Key Takeaways
Boston Scientific’s (BSX - Free Report) exited the third quarter of 2026 with $609 million in cash and approximately $11.95 billion in total debt, representing gross debt leverage of 1.9 times.
Adjusted gross margin contracted 300 basis points year over year to 68%, primarily due to unfavorable manufacturing absorption following the August cybersecurity incident. Adjusted operating margin declined 150 basis points to 26.5%, while the incident reduced quarterly adjusted earnings per share by approximately $0.07.
The company expects significant gross margin pressure in 2027, reflecting continued weakness in its Electrophysiology (EP) and WATCHMAN franchises, intensifying pricing pressure in China and ongoing operational investments. These factors could constrain operating cash flow growth and delay improvement in cash conversion.
Third-quarter free cash flow totaled $867 million. BSX lowered its full-year free cash flow outlook to approximately $3.6 billion, reflecting weaker operating income expectations.
The $2 billion accelerated share repurchase, $1.5-billion MiRus investment and pending Penumbra acquisition add to the company's financial commitments. With revenues and adjusted earnings growth expected to remain challenged in 2027, sustained margin pressure, elevated financing costs and acquisition-related obligations could limit financial flexibility.
Peer Update
Edwards Lifesciences (EW - Free Report) ended third-quarter 2026 with approximately $3.1 billion in cash and cash equivalents and about $600 million in debt. Operating cash flow reached $1.27 billion during the first nine months of 2026. The company repurchased approximately $700 million of shares through September and retained about $1.3 billion under its authorization. This liquidity supports continued investment in innovation, manufacturing and capital returns.
Medtronic (MDT - Free Report) ended first-quarter fiscal 2027 with $8.82 billion in cash and investments, compared with $2.54 billion in current debt obligations. Long-term debt also declined to $25.62 billion from $26.17 billion. During the quarter, the company paid $921 million in dividends and repurchased $267 million of shares. Medtronic maintained its quarterly dividend at $0.72 per share after raising it for fiscal 2027, marking the 49th consecutive year of dividend increases. The balance-sheet position supports continued investment in higher-growth areas and targeted acquisitions while preserving shareholder returns.
BSX Stock Price Performance
Shares of Boston Scientific have lost 56% over the past year compared with the industry’s decline of 21.5%. The S&P 500 composite has grown 10.4% over the same period.
Image Source: Zacks Investment Research
Boston Scientific’s Valuation
From a valuation standpoint, BSX trades at a forward 12-month price-to-sales ratio (P/S) of 3.00X, above the industry mean of 2.26X.
Image Source: Zacks Investment Research
Consensus Estimate Trend for BSX
The Zacks Consensus Estimate for BSX’s 2026 earnings has moved south 2.2% over the past 30 days.
Image Source: Zacks Investment Research
BSX stock currently has a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.